Positive results from ocrelizumab phase II RRMS study
Posted: Sat Oct 16, 2010 1:37 am
Roche and Biogen Idec announced 24-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease.
Ocrelizumab demonstrated a significant reduction in disease activity as measured by brain lesions and relapse rate. Patients with RRMS suffer from relapses and disabling symptoms caused by nerve damage which can significantly affect their quality of life.
“These efficacy results are amongst the most remarkable seen in a phase II RRMS study, and show that ocrelizumab may have the potential to offer benefits to patients with this disease”... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397